MOESM11 of Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinoma
2019-03-04T05:00:00Z (GMT) by
Additional file 11: Figure S9. The KaplanâMeier survival analysis of the signature for LUAD subgroup patients in GSE81089 dataset. Patients of high-risk exhibited poor prognosis in stage III cohort (Pâ<â0.05). There was no association of the risk score with patients of stage I cohort, stage II cohort, and stage IV cohort.